Is PIVKA-II a Promising Biomarker for Hepatocellular Carcinoma?
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F20%3A10410976" target="_blank" >RIV/00216208:11140/20:10410976 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00669806:_____/20:10410976
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=gFjC6EEako" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=gFjC6EEako</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Is PIVKA-II a Promising Biomarker for Hepatocellular Carcinoma?
Popis výsledku v původním jazyce
Aim. To evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for the diagnosis of hepatocellular carcinoma (HCC). The second aim was to compare PIVKA-II with routinely used alpha-fetoprotein (AFP) for the same indication. Materials and methods. 310 participants were enrolled in our study: 60 with HCC, 40 with liver metastases of colorectal cancer origin, 40 with liver cirrhosis, 20 with pancreatic cancer (PC) and 150 healthy individuals. Serum levels of PIVKA-II were measured using a chemiluminescent assay of the Architect 1000i System ("Abbott", USA) and AFP levels using a chemiluminescent assay by DxI 800 ("Beckman Coulter", USA). Serum concentrations of PIVKA-II and AFP were compared between the group with HCC and the other mentioned groups. Results. PIVKA-II achieved better clinical sensitivity in comparison with AFP. PIVKA-II achieved its best sensitivity (96,9 %) in distinguishing between the HCC and control group with the proposed cut-off value of 60 mAU/ml. Conclusion. PIVKA-II can be used alongside routinely established AFP as a valuable marker in the diagnosis of HCC.
Název v anglickém jazyce
Is PIVKA-II a Promising Biomarker for Hepatocellular Carcinoma?
Popis výsledku anglicky
Aim. To evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for the diagnosis of hepatocellular carcinoma (HCC). The second aim was to compare PIVKA-II with routinely used alpha-fetoprotein (AFP) for the same indication. Materials and methods. 310 participants were enrolled in our study: 60 with HCC, 40 with liver metastases of colorectal cancer origin, 40 with liver cirrhosis, 20 with pancreatic cancer (PC) and 150 healthy individuals. Serum levels of PIVKA-II were measured using a chemiluminescent assay of the Architect 1000i System ("Abbott", USA) and AFP levels using a chemiluminescent assay by DxI 800 ("Beckman Coulter", USA). Serum concentrations of PIVKA-II and AFP were compared between the group with HCC and the other mentioned groups. Results. PIVKA-II achieved better clinical sensitivity in comparison with AFP. PIVKA-II achieved its best sensitivity (96,9 %) in distinguishing between the HCC and control group with the proposed cut-off value of 60 mAU/ml. Conclusion. PIVKA-II can be used alongside routinely established AFP as a valuable marker in the diagnosis of HCC.
Klasifikace
Druh
J<sub>ost</sub> - Ostatní články v recenzovaných periodicích
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Astrachanskij medicinskij žurnal
ISSN
1992-6499
e-ISSN
—
Svazek periodika
15
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
RU - Ruská federace
Počet stran výsledku
4
Strana od-do
6-9
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—